125 related articles for article (PubMed ID: 37331413)
1. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
2. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.
Yen FS; Hou MC; Wei JC; Shih YH; Hwu CM; Hsu CC
BMC Med; 2024 Jan; 22(1):8. PubMed ID: 38172833
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
4. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
[TBL] [Abstract][Full Text] [Related]
6. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Engström A; Wintzell V; Melbye M; Svanström H; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Hviid A; Ueda P; Pasternak B
Hepatology; 2024 Jun; 79(6):1401-1411. PubMed ID: 38085855
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
Simon TG; Patorno E; Schneeweiss S
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
[TBL] [Abstract][Full Text] [Related]
8. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
12. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
[TBL] [Abstract][Full Text] [Related]
13. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
[TBL] [Abstract][Full Text] [Related]
14. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K
Aliment Pharmacol Ther; 2024 May; 59(9):1096-1110. PubMed ID: 38538967
[TBL] [Abstract][Full Text] [Related]
15. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
[TBL] [Abstract][Full Text] [Related]
16. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
17. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
18. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.
Yang YS; Chen HH; Huang CN; Hsu CY; Hu KC; Kao CH
Diabetes Care; 2022 May; 45(5):1184-1192. PubMed ID: 35275992
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
[TBL] [Abstract][Full Text] [Related]
20. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.
Stenberg E; Näslund E
Int J Obes (Lond); 2023 Apr; 47(4):251-256. PubMed ID: 36670155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]